Gelmetix

Gelmetix is a therapeutic biomaterials company based in the UK, with offices in London, Paris, and Manchester. Founded in 2012 as a spin-out from the University of Manchester, the company focuses on developing innovative polymer gel technologies to treat chronic pain conditions, particularly chronic lower back pain and osteoarthritis. The company specializes in creating various grades of polymer gel as non-invasive alternatives to surgery. Their lead product, DXM, is a hydrogel designed for nucleus pulposus augmentation, currently entering clinical trials. Another product, SXM, is in pre-clinical development. Gelmetix's patented technology not only aims to alleviate pain but also to restore joint movement, serving as a carrier for anti-inflammatories, stem cells, or other regenerative agents. Gelmetix is committed to providing effective, non-pharmacological treatments for chronic pain, addressing the opioid epidemic by offering minimally invasive solutions that target the underlying physical issues within the intervertebral disc.

• Employees8
• Founded2012
• Annual Revenue$2500000
• Total Funding$12834831